• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

15.13 +0.04 (+0.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,968,524
Open 15.17
Bid (Size) 14.93 (100)
Ask (Size) 15.40 (300)
Prev. Close 15.09
Today's Range 14.68 - 15.40
52wk Range 2.670 - 17.32
Shares Outstanding 121,613,181
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
April 02, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
March 19, 2026
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships. 
Via The Motley Fool

Performance

YTD
+85.0%
+85.0%
1 Month
+49.5%
+49.5%
3 Month
+99.3%
+99.3%
6 Month
+105.0%
+105.0%
1 Year
+372.8%
+372.8%

More News

Read More
News headline image
Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
March 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
Relay Therapeutics Inc (NASDAQ:RLAY) Beats Q4 Revenue Estimates, Outlines Pivotal 2026 for Zovegalisib ↗
February 26, 2026
Via Chartmill
News headline image
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
March 16, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗
February 27, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗
February 27, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
February 26, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
February 23, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
February 23, 2026
Via The Motley Fool
News headline image
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
February 19, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run ↗
February 06, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
February 03, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
February 02, 2026
Via MarketMinute
Topics ETFs Government Initial Public Offering
News headline image
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
December 12, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
December 16, 2025
From Equity Insider
Via GlobeNewswire
News headline image
Relay Therapeutics Director Sells $300,000 Worth of Shares. Here's Why Investors Shouldn't Panic. ↗
December 03, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗
December 03, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture
December 01, 2025
Via TokenRing AI
Topics Artificial Intelligence Economy Emissions
News headline image
Relay Therapeutics Inc (NASDAQ:RLAY) Reports Q3 2025 Earnings Miss and Clinical Progress ↗
November 06, 2025
Via Chartmill
Topics Earnings

Frequently Asked Questions

Is Relay Therapeutics, Inc. - Common Stock publicly traded?
Yes, Relay Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Relay Therapeutics, Inc. - Common Stock trade on?
Relay Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Relay Therapeutics, Inc. - Common Stock?
The ticker symbol for Relay Therapeutics, Inc. - Common Stock is RLAY on the Nasdaq Stock Market
What is the current price of Relay Therapeutics, Inc. - Common Stock?
The current price of Relay Therapeutics, Inc. - Common Stock is 15.13
When was Relay Therapeutics, Inc. - Common Stock last traded?
The last trade of Relay Therapeutics, Inc. - Common Stock was at 04/24/26 04:00 PM ET
What is the market capitalization of Relay Therapeutics, Inc. - Common Stock?
The market capitalization of Relay Therapeutics, Inc. - Common Stock is 1.84B
How many shares of Relay Therapeutics, Inc. - Common Stock are outstanding?
Relay Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap